Industry & Business

EpiCor Therapeutics wins UCD Start-up of the Year Award

 Breaking News
  • Technology Plays a Leading Role For Irish Business Leaders Business leaders across Ireland are firm believers in the power of technology and the important role it plays, not only in supporting their own business needs, but in overcoming the wider socioeconomic issues they face. According to research – Technology in a Transforming Ireland – of Irish business leaders commissioned by Fujitsu, nearly 6-in-10 (59 percent) say [...]...
  • Only 11% of Irish Businesses Using Renewable Energy Irish businesses have yet to make the switch to renewable energy but are looking for cleaner energy alternatives, according to new research from Calor Gas. Just 11% of Irish businesses report that they are using renewable energy. Of the businesses not using renewable energy, 85% are open to switching to a renewable alternative. The figures were [...]...
  • Research Reveals SMEs Lose €2.2 Billion a Year in Productivity Due to Administration Sage, a market leader in cloud accounting software, has revealed that Irish SMEs lose up to €2.2 billion annually in productivity due to burdensome administrative tasks. The report, ‘Sweating the Small Stuff: the impact of the bureaucracy burden’, undertaken by Plum Consulting, shows businesses in Ireland spend an average of 70 working-days per year navigating the [...]...
  • European Commission Takes Action For a More Competitive and Innovative Financial Market The European Commission has unveiled an Action Plan on how to harness the opportunities presented by technology-enabled innovation in financial services (FinTech). Europe should become a global hub for FinTech, with EU businesses and investors able to make most of the advantages offered by the Single Market in this fast-moving sector. As a first major deliverable, [...]...
  • 40% Think Irish Government Not Doing Enough to Protect Ireland From Impact of Brexit Brexit is coming closer and still a lot of questions remain unanswered. People are insecure not only about their own future but also the economic future of Ireland. iReach Insights conducted a nationally representative survey and 1,000 adults were asked about their opinion about the Brexit, it’s potential impact and what Irish people would do, [...]...

EpiCor Therapeutics wins UCD Start-up of the Year Award

EpiCor Therapeutics wins UCD Start-up of the Year Award
November 23
13:18 2016

Biotech start-up EpiCor Therapeutics won the UCD Start-Up of the Year Award 2016 on Thursday, November 17. It received a €20,000 prize as part of the overall winner award of the UCD VentureLaunch Accelerator Programme. The start-up is aiming to develop a treatment for hypertrophic obstructive cardiomyopathy (HOCM), a significant cause of sudden cardiac death.

HOCM is a disease in which a portion of the heart muscle is enlarged without any obvious cause resulting in impairment of the heart. Symptoms include shortness of breath, chest pain and heart palpitations. In the US alone, HOCM currently affects around 175,000 people with associated annual healthcare costs amounting to over $1 billion.

EpiCor Therapeutics is currently focused on repurposing an existing drug, 5-azacytidine, for the treatment of HOCM. It will also investigate the use of biomarkers to deliver targeted treatment for individuals.

EpiCor Therapeutics was founded by Dr John Baugh, Dr Nadia Glezeva, Dr Chris Watson, Dr Mark Ledwidge and Professor Ken McDonald, all of UCD School of Medicine.

“It is an honour for EpiCor Therapeutics to win the 2016 UCD Start-up of the Year Award,” said Dr John Baugh. “It is a great endorsement for us going forward as we work to develop treatments to target a variety of heart diseases, including our initial focus on hypertrophic obstructive cardiomyopathy.

The disease has no approved disease-modifying therapeutics, is a significant cause of sudden cardiac death of individuals in any age group and a leading cause of such death in young athletes.

EpiCor Therapeutics is now seeking to raise €750,000 in seed funding to enable pre-clinical bridging studies. Following additional fund raising, it plans to proceed with a clinical proof-of-concept study to support its approval as a treatment for HOCM.

UCD’s annual VentureLaunch Accelerator Programme aims to support and accelerate the launch of sustainable and profitable new ventures based on intellectual property emerging from the university.

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4